ChengDu Sheng Nuo Biotec (688117.SH) Subsidiary Obtains Certificate for Exporting APIs to the EU

ChengDu Sheng Nuo Biotec (688117.SH) announced that its wholly-owned subsidiary, Meishan Huilong Pharmaceutical Technology Co., Ltd. ("Meishan Huilong"), recently received the "Certificate of Export of APIs to the EU" approved and issued by the Sichuan Provincial Medical Products Administration, for the export to the EU of the human API: Tirzepatide. This time, the Tirzepatide API production line of the company's wholly-owned subsidiary Meishan Huilong successfully passed the on-site inspection by the Sichuan Provincial Medical Products Administration and successfully obtained the "Certificate of Export of APIs to the EU," indicating that the production quality management system of the company's wholly-owned subsidiary Meishan Huilong complies with China GMP requirements and is equivalent to compliance with EU, World Health Organization, and ICH Q7 pharmaceutical GMP standards. The obtaining of the above certificate is a high recognition of the company's R&D capabilities, production processes, and management level, provides key market access qualifications for the company's products to enter the EU market, helps the company expand its API business in the global market, enhances the company's competitiveness in the international market, and has positive significance for the company's long-term operation and steady development.